Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

120.38 +0.78 (+0.65%)

Streaming Delayed Price Updated: 1:43 PM EDT, Jun 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

3 Undervalued Names Too Cheap to Ignore ↗

March 07, 2026

Via MarketBeat

The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology

March 06, 2026

On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a...

Via Finterra

Topics Initial Public Offering Intellectual Property

Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗

March 05, 2026

Merck can help stabilize investors' portfolios, whereas ImmunityBio would be a source of volatility.

Via The Motley Fool

Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era

March 05, 2026

Today’s Date: March 5, 2026 Introduction The narrative surrounding Moderna, Inc. (NASDAQ: MRNA) shifted dramatically this morning as the biotechnology pioneer’s shares surged 15.99%, reclaiming a level...

Via Finterra

Topics Intellectual Property

ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth

March 04, 2026

In a classic case of "selling the news," shares of ImmunityBio, Inc. (NASDAQ: IBRX) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise...

Via MarketMinute

Topics Earnings Economy

2 High-Flying Stocks With More Upside to Buy and Hold ↗

March 04, 2026

It's not too late to get in on the action.

Via The Motley Fool

Topics Artificial Intelligence Supply Chain

IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗

March 03, 2026

To address the BCG shortage, ImmunityBio highlighted its recombinant BCG program, with 580 patients enrolled across about 100 clinical sites.

Via Stocktwits

Topics Earnings Supply Chain

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

March 03, 2026

The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva.

Via Stocktwits

Topics Artificial Intelligence

USDA Deploys $100 Million 'Screwworm Challenge' to Safeguard U.S. Livestock and Dairy Frontier

March 02, 2026

The United States Department of Agriculture (USDA) has officially greenlit a massive $100 million initiative dubbed the "Screwworm Challenge," aimed at neutralizing a resurgent biological threat that...

Via MarketMinute

Topics Economy

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗

March 02, 2026

Founder Patrick Soon-Shiong spotlighted Anktiva on national TV, emphasizing IL-15’s potential to activate the immune system and its combination approach with Merck’s Keytruda.

Via Stocktwits

Topics Artificial Intelligence

KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

February 28, 2026

From Merck & Co., Inc

Via Business Wire

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

February 28, 2026

From Merck & Co., Inc.

Via Business Wire

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗

February 28, 2026

The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics.

Via The Motley Fool

Topics Lawsuit

Big Tech’s Heavy Lifting: S&P 500 Q4 Earnings Surpass 8% Growth Amid AI Capex Anxiety

February 27, 2026

As the final reports of the fourth-quarter earnings season trickled in through late February 2026, the S&P 500 demonstrated a resilient performance that caught many analysts by surprise. The benchmark...

Via MarketMinute

Topics Artificial Intelligence Economy Electric Vehicles

What's going on in today's session: S&P500 movers ↗

February 27, 2026

Via Chartmill

Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag

February 27, 2026

The fourth-quarter 2025 earnings season has delivered a definitive verdict on the health of the American economy: the "Industrial Renaissance" is no longer a forecast, but a realized phenomenon. While...

Via MarketMinute

Topics Artificial Intelligence Economy

KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

February 27, 2026

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

February 27, 2026

From Merck & Co., Inc.

Via Business Wire

Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results

February 26, 2026

Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir...

Via MarketMinute

Topics Intellectual Property

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...

Via MarketMinute

Topics Economy Intellectual Property

The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough

February 26, 2026

United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company...

Via Finterra

Topics Earnings Economy Intellectual Property

United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’

February 26, 2026

As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance

February 25, 2026

The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir,...

Via MarketMinute

Topics Intellectual Property

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Via MarketMinute

Topics Intellectual Property

FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis

February 25, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

February 25, 2026

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Evolves Human Health Operating Structure to Support Portfolio Execution

February 23, 2026

From Merck & Co., Inc.

Via Business Wire

Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗

February 23, 2026

According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.

Via Stocktwits

Topics Intellectual Property

Merck: This Cancer‑Drug Powerhouse Could Be a Core Dividend Holding for Decades ↗

February 22, 2026

The company might bend, but it won't break.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.